Market Intelligence, Clinical Progress, and High-Purity Reagents for Angiogenesis & Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NRP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NRP1 ECD-Fc Fusion Protein / Mutant Protein. High purity (>95%), Endotoxin <1EU/μg, Sequence Verified. HEK293 Expressed (Native Glycosylation). | View NRP1 Products |
| Gene Delivery | NRP1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Ideal for internalization & Treg modulation assays. | View NRP1 Products |
| Benchmark Ab | Anti-NRP1 Reference Antibody (Vesencumab-class biosimilar sequence). Recombinant positive control for assay standardization. | View NRP1 Products |
| Counter-Screen | NRP2 ECD-Fc Protein. For selectivity validation vs. close homolog (55% ECD identity). | View NRP2 Products |
| Ligand Control | VEGFA165 Protein. Validated ligand for competitive binding assays. | View VEGFA Products |
| Ligand Control | SEMA3A Protein. Axon guidance ligand for functional blocking studies. | View SEMA3A Products |
| Co-Receptor | VEGFR2 (KDR) ECD-Fc. For heterodimerization & bridging assays. | View KDR Products |
| Validator | NRP1 siRNA Set. For knockdown verification & specificity controls. | View NRP1 Products |
Critical Assay Challenge vs. TarMart Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Toxicology Evaluation | Human/Mouse/Cyno NRP1 ortholog proteins available with >95% purity, Sequence Verified. |
| NRP2 Selectivity (Avoid Neurological Off-Target) | Homolog panel: NRP1 vs NRP2 proteins strictly verified by Mass Spec for off-target liability screening. |
| ADC Internalization Efficiency | HEK293 Expressed Full-Length Lentivirus for high-expression cell lines (Flow Cytometry/Confocal compatible). |
| Dual Ligand Displacement (VEGF vs Sema3A) | Domain-specific constructs (b1 vs b2) available upon custom request; Native conformation ECD-Fc preserves both binding sites. |
| Lack of Clinical Benchmark Controls | Anti-NRP1 Reference Antibody (Vesencumab-class biosimilar sequence) available for assay standardization. |
| Preservation of Native Conformation | HEK293 Expressed (Native Glycosylation), Theoretical MW maintained. |
| False Positives in Screening | Sequence Verified antigens and Validated siRNA included for specificity checks. |
Live NRP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The NRP1 therapeutic landscape is transitioning from pure anti-angiogenic strategies (VEGF blockade) to dual-mode immuno-oncology interventions targeting tumor-associated Tregs and macrophages. As first-generation monotherapies (e.g., anti-NRP1 mAbs) demonstrate limited efficacy as single agents, the R&D focus has shifted toward bispecific constructs (PD-1/NRP1) and ADCs leveraging NRP1's rapid internalization properties. The next wave of development emphasizes combination with VEGFR2 inhibitors and radioligand therapies for glioblastoma and metastatic colorectal cancer. As an essential co-receptor for VEGF and Semaphorin pathways, NRP1 plays a crucial role in tumor angiogenesis, immune evasion (Treg modulation), and viral entry, making it a promising target for synergistic pathway blockade to overcome anti-VEGF resistance and enhance immune checkpoint inhibitor efficacy in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Genentech/Roche, Nanjing IASO | Solid Tumors, Vascular Diseases | Ligand Blocking Assay (Need High-Purity ECD-Fc) |
| Bispecifics (NRP1 x PD-1) | Emerging Innovators | Immunotherapy Refractory Tumors | Heterodimer Validation (Need Cross-reactive Abs) |
| ADC | Oncology Pipelines | NRP1-Overexpressing Cancers | Internalization Assay (Sequence Verified Receptors) |